NST-628 demonstrates superior anti-cancer activity in animal models for multiple tumor types and potential for daily dosing NST-628 broadly penetrates the CNS in animal models NST-628 robustly and durably decreases RAS/MAPK pathway reactivation IND filing expected in first half of 2024…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.